By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a way that, while positioned as a public health measure, also grants investors ...

While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...

We are a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases through cell therapy. Cell therapy is a process of using a patient’s own cells to better ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting neurological diseases. Some failures split up partners, and one particularly ...